Press coverage about PRA Health Sciences (NASDAQ:PRAH) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PRA Health Sciences earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 47.4383149942422 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern’s analysis:
- Zacks: Analysts Anticipate PRA Health Sciences Inc (PRAH) Will Announce Quarterly Sales of $730.90 Million (americanbankingnews.com)
- PRA Health Sciences Inc (PRAH) Major Shareholder Sells $656,565,000.00 in Stock (americanbankingnews.com)
- Zacks: Brokerages Anticipate PRA Health Sciences Inc (PRAH) to Post $1.08 Earnings Per Share (americanbankingnews.com)
- PRA Health Sciences (PRAH) PT Set at $100.00 by Mizuho (americanbankingnews.com)
A number of equities research analysts recently issued reports on PRAH shares. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 27th. Zacks Investment Research upgraded shares of PRA Health Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 1st. Jefferies Financial Group reiterated a “buy” rating and set a $115.00 target price on shares of PRA Health Sciences in a research report on Friday, July 20th. ValuEngine upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th. Finally, Mizuho set a $100.00 target price on shares of PRA Health Sciences and gave the stock a “hold” rating in a research report on Monday, August 6th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average price target of $105.20.
PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, August 1st. The medical research company reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.12. The business had revenue of $722.84 million during the quarter, compared to analysts’ expectations of $706.57 million. PRA Health Sciences had a net margin of 4.25% and a return on equity of 24.52%. The firm’s revenue for the quarter was up 35.4% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. equities research analysts forecast that PRA Health Sciences will post 3.89 EPS for the current fiscal year.
In other PRA Health Sciences news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the firm’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $101.01, for a total value of $656,565,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.